Apogee Therapeutics share price logo

Apogee Therapeutics Share Price

NASDAQ: APGE

Mid Cap

$39.85

+0.24

(+0.62%)

as on

Apogee Therapeutics Stock Performance

as on October 4, 2025 at 1:29 am IST

  • Day's Low

    Day's High

    $39.35
    $40.42
    downward going graph

    1.25%

    Downside

    1.43%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $26.2
    $63.5
    downward going graph

    34.25%

    Downside

    59.35%

    Upside

    downward going graph

Apogee Therapeutics share price movements today

Previous Close
$39.61
Open
$39.95
Volume
379.5K
Day's Low - High
$39.35 - $40.42
52 Week Low - High
$26.2 - $63.5

Apogee Therapeutics Historical Returns

1 Month Return
+ 7.41 %
3 Month Return
-15.97 %
1 Year Return
-26.8 %
3 Year Return
0 %
5 Year Return
0 %

Apogee Therapeutics Stock Fundamentals & Key Indicators

Check Apogee Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.4B

EPS (TTM)

-4.4782

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

P/B Ratio

0

PEG Ratio

0

EBITDA

-270.1M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

7526700.00%

Apogee Therapeutics stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Apogee Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
BUY$2.4BNANA0.00%

Stock Returns calculator for Apogee Therapeutics Stock including INR - Dollar returns

The Apogee Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

Apogee Therapeutics investment value today

Current value as on today

₹78,919

Returns

₹21,081

(-21.08%)

Returns from Apogee Therapeutics Stock

₹26,854 (-26.85%)

Dollar Returns*

₹5,773 (+5.77%)

Analyst Recommendation on Apogee Therapeutics Stock

Based on 12 analysts

BUY

91.67%

Buy

8.33%

Hold

0.00%

Sell

Based on 12 analysts, 91.67% of analysts recommend a 'BUY' rating for Apogee Therapeutics. Average target price of $93.67

Apogee Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Apogee Therapeutics.

What analysts predicted

57.46%UPSIDE

Target Price

$93.67

Current Price

$39.85

Analyzed by

12 Analysts

Target

$93.67

Apogee Therapeutics target price $93.67, a slight upside of 57.46% compared to current price of $39.85. According to 12 analysts rating.

Apogee Therapeutics Stock’s Investor Sentiment and Interest

Search interest for Apogee Therapeutics Stock has increased by 17% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:17% versus previous 30 day period

Apogee Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2023
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Total Revenue
-
-
-
-
-
-
-
0
-
-
Gross Profit
-
-
-
-
0
0
0
0
0
0
Operating Income
-12
-18
-24
-37
-38
-44
-58
-75
-63
-73
EBITDA
-12
-18
-20
-31
-38
-44
-58
-75
-63
-73
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
-
-
-
-
0
0
0
0
0
0
Income Before Tax
-12
-18
-20
-31
-32
-33
-49
-67
-55
0
Income Tax Expense
0
0
3
0
0
-
-
0
0
0
Net Income
-12
-18
-20
-31
-32
-33
-49
-67
-55
-66
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
-51706.15%
0.00%
0.00%

Apogee Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2022
Dec 2023
Dec 2024
Total Revenue
-
-
-
Gross Profit
-
-
0
Operating Income
-30
-93
-216
EBITDA
-39
-83
-216
Interest Expense
9
-
-
Depreciation
-
-
0
Income Before Tax
-39
-83
-182
Income Tax Expense
0
0
0
Net Income
-39
-83
-182
Net Profit Margin
0.00%
0.00%
0.00%

Apogee Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2023
Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Net Income
-18
-20
-31
-32
-33
-49
-67
-55
-66
Operating Cash Flow
-14
-19
-29
-31
-29
-42
-67
-48
-62
Investing Cash Flow
-
-234
-273
-51
-148
-146
46
12
78
Financing Cash Flow
-1
317
0
450
0
0
44
0
1
Change in Cash
-16
63
-69
367
-178
-188
23
-34
17

Apogee Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2023
Dec 2024
Net Income
-83
-182
Operating Cash Flow
-74
-171
Investing Cash Flow
-273
-300
Financing Cash Flow
315
495
Change in Cash
-33
23

About Apogee Therapeutics

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Rα. APG279 is for the dual inhibition of OX40L and IL-13.
OrganisationApogee Therapeutics
HeadquartersBuilding 17, Waltham, MA, United States, 02453
CEODr. Michael Thomas Henderson M.D.
E-voting on sharesClick here to vote

Key Management of Apogee Therapeutics

Name

Title

Ms. Jane Pritchett V. Henderson

Chief Financial Officer

Mr. Matthew Batters J.D.

Chief Legal Officer & Corporate Secretary

Ms. Emily Cox

SVP & Head of People

Ms. Wendy Aspden-Curran

Senior Vice President of Clinical Operations

Ms. Monica Forbes

Senior Vice President of Finance

Dr. Michael Thomas Henderson M.D.

CEO & Director

Dr. Carl Linden Dambkowski M.D.

Chief Medical Officer

Ms. Noel Kurdi

Vice President of Investor Relations

Dr. Rebecca Dabora Ph.D.

Chief Development Officer

Dr. Drew Badger Ph.D.

Senior VP and Head of Regulatory Affairs & Toxicology

FAQs

What is Apogee Therapeutics share price today?

Apogee Therapeutics share price today is $39.85 as on at the close of the market. Apogee Therapeutics share today touched a day high of $40.42 and a low of $39.35.

What is the 52 week high and 52 week low for Apogee Therapeutics share?

Apogee Therapeutics share touched a 52 week high of $63.5 on and a 52 week low of $26.2 on . Apogee Therapeutics stock price today i.e. is closed at $39.85,which is 37.24% down from its 52 week high and 52.10% up from its 52 week low.

What is Apogee Therapeutics's market capitalisation today?

Apogee Therapeutics market capitalisation is $0.00T as on .

How to invest in Apogee Therapeutics Stock (APGE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Apogee Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Apogee Therapeutics Shares that will get you 0.0376 shares as per Apogee Therapeutics share price of $39.85 per share as on October 4, 2025 at 1:29 am IST.

What is the minimum amount required to buy Apogee Therapeutics Stock (APGE) from India?

Indian investors can start investing in Apogee Therapeutics (APGE) shares with as little as ₹88.775 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹887.75 in Apogee Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Apogee Therapeutics share’s latest price of $39.85 as on October 4, 2025 at 1:29 am IST, you will get 0.2509 shares of Apogee Therapeutics. Learn more about fractional shares .